The impact of Clostridium butyricum MIYAIRI 588 on the murine gut microbiome and colonic tissue

Hagihara, Mao; Yamashita, Ryoko; Matsumoto, Asako; Mori, Takeshi; Kuroki, Yasutoshi; Kudo, Hayami; Oka, Koichiro; Takahashi, Motomichi; Nonogaki, Tsunemasa; Yamagishi, Yuka; Mikamo, Hiroshige

doi:10.1016/j.anaerobe.2018.07.012

Cited by 44 publications

(51 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While several studies indicate no effect of C. butyricum supplementation on metrics of community composition (diversity indices, clustering in PCA/PCoA analysis), 14,22,23 others show a pronounced effect on diversity and/or a distinct community composition post supplementation. 12,15,20,21,24,25 Some of these differences might be methodological, for example PCR-DGGE data from models of antibiotic-associated diarrhea indicate increased diversity following C. butyricum supplementation while, in similar models, illumina 16S rRNA gene sequencing data do not.…”

Section: Butyricum and Modulation Of The Gut Microbiomementioning

confidence: 99%

Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease

Stoeva¹,

Garcia-So²,

Justice³

et al. 2021

Gut Microbes

181

156

View full text Add to dashboard Cite

Clostridium butyricum is a butyrate-producing human gut symbiont that has been safely used as a probiotic for decades. C. butyricum strains have been investigated for potential protective or ameliorative effects in a wide range of human diseases, including gut-acquired infection, intestinal injury, irritable bowel syndrome, inflammatory bowel disease, neurodegenerative disease, metabolic disease, and colorectal cancer. In this review we summarize the studies on C. butyricum supplementation with special attention to proposed mechanisms for the associated health benefits and the supporting experimental evidence. These mechanisms center on molecular signals (especially butyrate) as well as immunological signals in the digestive system that cascade well beyond the gut to the liver, adipose tissue, brain, and more. The safety of probiotic C. butyricum strains appears well-established. We identify areas where additional human randomized controlled trials would provide valuable further data related to the strains' utility as an intervention.

show abstract

Section: Butyricum and Modulation Of The Gut Microbiomementioning

confidence: 99%

Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease

Stoeva¹,

Garcia-So²,

Justice³

et al. 2021

Gut Microbes

181

156

View full text Add to dashboard Cite

show abstract

“…In subgroup analysis of patients with or without antibiotic therapy prior to initiation of ICB, the impact of probiotic CBT on patients' survival were more significant in cancer patients who receiving antibiotic therapy than those who did not receiving antibiotic therapy , suggesting that a clinical setting of probiotic CBT under the condition of antibiotic use may be necessary to maximize the benefit from probiotic CBT and detect a beneficial effect of probiotic CBT. Probiotic CBT improve dysbiosis under the condition of antibiotic therapies (8)(9)(10)(11)(13)(14)(15). Bifidobacterium, which promotes antitumor immunity and facilitates efficacy of ICB, is significantly increased in combination with probiotic CBT and clindamycin when compared with only probiotic CBT (13,15), suggesting that a combination therapy of probiotic CBT with antibiotics to deplete microbial communities could potentially improve responses to ICB therapy (20).…”

Section: Clostridium Butyricum Increasesmentioning

confidence: 99%

Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer

Tomita

Ikeda

Sakata

et al. 2020

Cancer Immunology Research

126

120

View full text Add to dashboard Cite

Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB). Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium butyricum MIYAIRI 588 strain is a probiotic therapy used to improve symptoms related to antibiotic-induced dysbiosis in Japan. We hypothesized that probiotic Clostridium butyricum therapy (CBT) may affect the therapeutic efficacy of ICBs. We retrospectively evaluated 118 advanced non-small cell lung cancer patients treated with ICBs at Kumamoto University Hospital. Survival analysis comparing patients given CBT before and/or after ICB was conducted using univariate analyses and Cox proportional hazards regression models using propensity score. Propensity score analyses confirmed that probiotic CBT treatment significatnly prolonged PFS and and OS. Probiotic CBT significantly associated with longer PFS and OS even in patients who received antibiotic therapy. This study suggests that probiotic CBT may have a positive impact on therapeutic efficacy of ICB in cancer patients. Research.

show abstract

“…In addition to these bacteria, yeast ( Saccharomyces cerevisiae ) and molds ( Aspergillus niger and Aspergillus oryzae ) were also reported as DFM (7). Moreover, certain strains of Clostridium such as Clostridium butyricum MIYAIRI 588 were also used as potential probiotics (8). Unlike other bacteria whose vegetative cells are used as DFM, spores from Bacillus sps.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Antimicrobial and Anti-inflammatory Properties of Bacillus-DFM (Norum™) in Broiler Chickens Infected With Salmonella Enteritidis

et al. 2019

View full text Add to dashboard Cite

Restrictions of in-feed antibiotics use in poultry has pushed research toward finding appropriate alternatives such as Direct-Fed Microbials (DFM). In this study, previously tested Bacillus isolates ( B . subtilis and B . amyloliquefaciens ) were used to evaluate their therapeutic and prophylactic effects against Salmonella enterica serovar Enteritidis ( S . Enteritidis) in broiler chickens. For this purpose, initial antibacterial activity of Bacillus -DFM (10 4 spores/g or 10 6 spores/g) against S . Enteritidis colonization in crop, proventriculus and intestine was investigated using an in vitro digestive model. Furthermore, to evaluate therapeutic and prophylactic effects of Bacillus -DFM (10 4 spores/g) against S . Enteritidis colonization, altogether 60 ( n = 30/group) and 30 ( n = 15/group) 1-day-old broiler chickens were randomly allocated to either DFM or control group (without Bacillus -DFM), respectively. Chickens were orally gavaged with 10 4 cfu of S . Enteritidis per chicken at 1-day old, and cecal tonsils (CT) and crop were collected 3 and 10 days later during the therapeutic study, whereas they were orally gavaged with 10 7 cfu of S . Enteritidis per chicken at 6-day-old, and CT and crop were collected 24 h later from two independent trials during the prophylactic study. Serum superoxide dismutase (SOD), FITC-d and intestinal IgA levels were reported for both chicken studies, in addition cecal microbiota analysis was performed during the therapeutic study. DFM significantly reduced S . Enteritidis concentration in the intestine compartment, and in both proventriculus and intestine compartments as compared to the control when used at 10 4 spores/g and 10 6 spores/g, respectively ( p < 0.05). DFM significantly reduced FITC-d and IgA as well as SOD and IgA levels ( p < 0.05) compared to the control in therapeutic and prophylactic studies, respectively. Interestingly, in the therapeutic study, there were significant differences in bacterial community structure and predicted metabolic pathways between DFM and control. Likewise, phylum Actinobacteria and the genera Bifidobacterium, Roseburia, Proteus , and cc_115 were decreased, while the genus Streptococcus was enriched significantly in the DFM group as compared to the control (MetagenomeSeq, p < 0.05). Thus, the overall results suggest that the ...

show abstract

The impact of Clostridium butyricum MIYAIRI 588 on the murine gut microbiome and colonic tissue

Cited by 44 publications

References 31 publications

Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease

Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease

Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer

Evaluation of the Antimicrobial and Anti-inflammatory Properties of Bacillus-DFM (Norum™) in Broiler Chickens Infected With Salmonella Enteritidis

Contact Info

Product

Resources

About